IMA questions govt on ayurveda, yoga-based treatment of Covid-19

IMA questioned the scientific basis of the government's recently released protocol based on ayurveda and yoga for the prevention as well as treatment of asymptomatic and mild patients of COVID-19.

IMA questions govt on ayurveda, yoga-based treatment of Covid-19
Press Trust of India New Delhi
2 min read Last Updated : Oct 08 2020 | 10:36 PM IST

The Indian Medical Association on Thursday questioned the scientific basis of the government's recently released protocol based on ayurveda and yoga for the prevention as well as treatment of asymptomatic and mild patients of COVID-19.

Union Health Minister Harsh Vardhan on Tuesday released a protocol for the clinical management of COVID-19, that lists dietary measures, yoga and ayurvedic herbs and formulations such as Ashwagandha and AYUSH-64 for prevention of coronavirus infection and treatment of mild and asymptomatic cases.

"Whether the proponents of this claim and his Ministry are prepared to subject themselves as volunteers to an independent prospective double-blind control study in prevention and treatment of COVID? How many of his ministerial colleagues have so far made the informed choice of getting treated under these protocols?" the IMA asked.

"What is stopping him from handing over COVID care and control to AYUSH ministry? IMA demands that the Union Health Minister should come clean on the above posers. If not, he is inflicting a fraud on the nation and gullible patients by calling placebos as drugs," it added.

Questioning the scientific basis of these protocols, the IMA has asked the health minister "to give reproducibility of a claim elsewhere in non-conflict situations and double blind control studies".

A double blind study is a randomized clinical trial in which the person does not know if they are receiving the experimental treatment, a standard treatment or a placebo. Placebo is a substance or treatment which is designed to have no therapeutic value.

"Is there satisfactory evidence regarding the claims made from studies done on COVID-19 patients based on the above criteria? If so, whether the evidence is weak or moderate or strong? The evidence should be in public domain and available for scientific scrutiny," it said in a statement.

The IMA asked "whether the severe form of COVID-19 a hyperimmune status or an immune deficiency status?"

The IMA demanded that the Union Health Minister respond to these posers. "If not, he is inflicting a fraud on the nation and gullible patients by calling placebos as drugs," it said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirusindian medical association

First Published: Oct 08 2020 | 10:32 PM IST

Next Story